Nimra (Tranexamic Acid)

Tranexamic Acid, the active ingredient in Nimra, is an antifibrinolytic presented as an oral formulation for prescription use. It reduces fibrinolysis by inhibiting plasmin formation, thereby stabilizing blood clots. Clinically, it is employed to control excessive menstrual bleeding, minimize intra‑operative blood loss, and manage trauma‑related hemorrhage under physician guidance.

GNH USA supplies Nimra as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU quality standards and provides reliable logistics for global distribution.

Tranexamic Acid is used to reduce bleeding in several clinical situations involving the hemostatic pathway. - Menorrhagia: helps reduce the volume and duration of menstrual bleeding in women with heavy periods. - Surgical bleeding: decreases intra‑operative blood loss and the need for transfusion during various surgical procedures. - Trauma-related hemorrhage: assists in controlling acute bleeding following traumatic injuries.

Tranexamic Acid may be associated with several adverse reactions, ranging from mild to serious.

Common Side Effects: - Nausea: mild stomach upset or queasiness. - Vomiting: occasional expulsion of stomach contents. - Diarrhea: loose stools or increased bowel movements. - Headache: transient cranial discomfort. - Dizziness: feeling of light‑headedness or unsteadiness.

Serious or Rare Side Effects: - Thromboembolic events: formation of abnormal blood clots in veins or arteries. - Vision disturbances: blurred vision or visual field changes. - Allergic reactions: rash, itching, swelling, or anaphylaxis. - Hypotension: sudden drop in blood pressure, especially with rapid intravenous administration.

When prescribing Tranexamic Acid, certain precautions should be observed to ensure safe use. - Assess thrombotic risk: evaluate patient history for deep‑vein thrombosis, pulmonary embolism, or cardiovascular disease. - Monitor renal function: adjust use in patients with impaired kidney clearance. - Use with caution in pregnancy: consider potential risks and benefits before prescribing. - Avoid in active intravascular clotting: contraindicated in patients with ongoing thrombus formation. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Tranexamic Acid can interact with other medicines, influencing efficacy or safety.

Major Interactions (Avoid): - Contraceptive hormonal agents: may increase risk of thrombosis when combined with estrogen‑containing products. - Direct factor Xa inhibitors (e.g., apixaban, rivaroxaban): heightened potential for clot formation. - Anticoagulants (warfarin, heparin): may reduce anticoagulant effect and alter INR.

Moderate Interactions (Monitor Closely): - Antiplatelet drugs (aspirin, clopidogrel): monitor for additive bleeding control or clotting changes. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): observe for gastrointestinal irritation. - CYP450 substrates: potential for altered metabolism, requiring dose adjustments.